TMEM71 Polyclonal antibody
TMEM71 Polyclonal Antibody for IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human
Applications
IHC, ELISA
Conjugate
Unconjugated
Cat no : 16722-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive IHC detected in | human prostate cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
Application | Dilution |
---|---|
Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
IHC | See 1 publications below |
Product Information
16722-1-AP targets TMEM71 in IHC, ELISA applications and shows reactivity with human samples.
Tested Reactivity | human |
Cited Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | TMEM71 fusion protein Ag10161 相同性解析による交差性が予測される生物種 |
Full Name | transmembrane protein 71 |
Calculated molecular weight | 232 aa, 26 kDa |
GenBank accession number | BC105783 |
Gene symbol | TMEM71 |
Gene ID (NCBI) | 137835 |
RRID | AB_2878304 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
TMEM71 is a transmembrane protein which was found to be associated with the glucocorticoids (GC) response status of the Acute Graft-versus-Host Disease (aGvHD) patients.
Protocols
Product Specific Protocols | |
---|---|
IHC protocol for TMEM71 antibody 16722-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Hum Cell Identification and validation of an m6A-related gene signature to predict prognosis and evaluate immune features of breast cancer |